{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T01:20:11Z","timestamp":1793064011100,"version":"4.5.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,3,3]],"date-time":"2023-03-03T00:00:00Z","timestamp":1677801600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,3]],"date-time":"2023-03-03T00:00:00Z","timestamp":1677801600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP20kk0305014"],"award-info":[{"award-number":["JP20kk0305014"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Japan Society for Fertility Preservation"},{"name":"Heart Link Working Project"},{"name":"St. Marianna University School of Medicine Research grant","id":[{"id":"https:\/\/ror.org\/043axf581","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100008542","name":"Children\u2019s Cancer Association of Japan","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100008542","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004721","name":"The University of Tokyo","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004721","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Minimal residual disease (MRD) is usually defined as the small number of cancer cells that remain in the body after treatment. The clinical significance of MRD kinetics is well recognized in treatment of hematologic malignancies, particularly acute lymphoblastic leukemia (ALL). Real time quantitative PCR targeting immunoglobulin (Ig) or T-cell receptor (TCR) rearrangement (PCR-MRD), as well as multiparametric flow cytometric analysis targeting antigen expression, are widely used in MRD detection. In this study, we devised an alternative method to detect MRD using droplet digital PCR (ddPCR), targeting somatic single nucleotide variants (SNVs). This ddPCR-based method (ddPCR-MRD) had sensitivity up to 1E-4. We assessed ddPCR-MRD at 26 time points from eight T-ALL patients, and compared it to the results of PCR-MRD. Almost all results were concordant between the two methods, but ddPCR-MRD detected micro-residual disease that was missed by PCR-MRD in one patient. We also measured MRD in stored ovarian tissue of four pediatric cancer patients, and detected 1E-2 of submicroscopic infiltration. Considering the universality of ddPCR-MRD, the methods can be used as a complement for not only ALL, but also other malignant diseases regardless of tumor-specific Ig\/TCR or surface antigen patterns.<\/jats:p>","DOI":"10.1007\/s12185-023-03566-2","type":"journal-article","created":{"date-parts":[[2023,3,3]],"date-time":"2023-03-03T03:03:14Z","timestamp":1677812594000},"page":"910-918","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Minimal residual disease detection by mutation-specific droplet digital PCR for leukemia\/lymphoma"],"prefix":"10.1007","volume":"117","author":[{"given":"Ryota","family":"Shirai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoo","family":"Osumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dai","family":"Keino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiko","family":"Nakabayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Uchiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Sekiguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuteru","family":"Hiwatari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaoru","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1520-7007","authenticated-orcid":false,"given":"Daisuke","family":"Tomizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seido","family":"Takae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobutaka","family":"Kiyokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimikazu","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takako","family":"Yoshioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichiro","family":"Hata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshinori","family":"Hori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nao","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5145-1774","authenticated-orcid":false,"given":"Motohiro","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,3]]},"reference":[{"issue":"9102","key":"3566_CR1","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/s0140-6736(97)10295-1","volume":"351","author":"E Coustan-Smith","year":"1998","unstructured":"Coustan-Smith E, Behm FG, Sanchez J, Boyett JM, Hancock ML, Raimondi SC, et al. Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia. Lancet. 1998;351(9102):550\u20134. https:\/\/doi.org\/10.1016\/s0140-6736(97)10295-1.","journal-title":"Lancet"},{"issue":"4","key":"3566_CR2","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/s1470-2045(15)70082-3","volume":"16","author":"CH Pui","year":"2015","unstructured":"Pui CH, Pei D, Coustan-Smith E, Jeha S, Cheng C, Bowman WP, et al. Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study. Lancet Oncol. 2015;16(4):465\u201374. https:\/\/doi.org\/10.1016\/s1470-2045(15)70082-3.","journal-title":"Lancet Oncol"},{"issue":"9142","key":"3566_CR3","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1016\/s0140-6736(98)04058-6","volume":"352","author":"JJ van Dongen","year":"1998","unstructured":"van Dongen JJ, Seriu T, Panzer-Gr\u00fcmayer ER, Biondi A, Pongers-Willemse MJ, Corral L, et al. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet. 1998;352(9142):1731\u20138. https:\/\/doi.org\/10.1016\/s0140-6736(98)04058-6.","journal-title":"Lancet"},{"issue":"22","key":"3566_CR4","doi-asserted-by":"publisher","first-page":"3650","DOI":"10.1200\/jco.2008.20.1533","volume":"27","author":"D Grimwade","year":"2009","unstructured":"Grimwade D, Jovanovic JV, Hills RK, Nugent EA, Patel Y, Flora R, et al. Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy. J Clin Oncol: Off J Am Soc Clin Oncol. 2009;27(22):3650\u20138. https:\/\/doi.org\/10.1200\/jco.2008.20.1533.","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"issue":"12","key":"3566_CR5","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1016\/s1470-2045(18)30580-1","volume":"19","author":"U Platzbecker","year":"2018","unstructured":"Platzbecker U, Middeke JM, Sockel K, Herbst R, Wolf D, Baldus CD, et al. Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial. Lancet Oncol. 2018;19(12):1668\u201379. https:\/\/doi.org\/10.1016\/s1470-2045(18)30580-1.","journal-title":"Lancet Oncol"},{"issue":"24","key":"3566_CR6","doi-asserted-by":"publisher","first-page":"3679","DOI":"10.1182\/blood-2015-03-635169","volume":"125","author":"DM Kurtz","year":"2015","unstructured":"Kurtz DM, Green MR, Bratman SV, Scherer F, Liu CL, Kunder CA, et al. Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing. Blood. 2015;125(24):3679\u201387. https:\/\/doi.org\/10.1182\/blood-2015-03-635169.","journal-title":"Blood"},{"issue":"5","key":"3566_CR7","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/s1470-2045(15)70106-3","volume":"16","author":"M Roschewski","year":"2015","unstructured":"Roschewski M, Dunleavy K, Pittaluga S, Moorhead M, Pepin F, Kong K, et al. Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study. Lancet Oncol. 2015;16(5):541\u20139. https:\/\/doi.org\/10.1016\/s1470-2045(15)70106-3.","journal-title":"Lancet Oncol"},{"issue":"364","key":"3566_CR8","doi-asserted-by":"publisher","first-page":"364ra155","DOI":"10.1126\/scitranslmed.aai8545","volume":"8","author":"F Scherer","year":"2016","unstructured":"Scherer F, Kurtz DM, Newman AM, Stehr H, Craig AF, Esfahani MS, et al. Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA. Sci Transl Med. 2016;8(364):364ra155. https:\/\/doi.org\/10.1126\/scitranslmed.aai8545.","journal-title":"Sci Transl Med."},{"issue":"18","key":"3566_CR9","doi-asserted-by":"publisher","first-page":"5374","DOI":"10.1158\/1078-0432.ccr-16-2647","volume":"23","author":"A Marachelian","year":"2017","unstructured":"Marachelian A, Villablanca JG, Liu CW, Liu B, Goodarzian F, Lai HA, et al. Expression of five neuroblastoma genes in bone marrow or blood of patients with relapsed\/refractory neuroblastoma provides a new biomarker for disease and prognosis. Clin Cancer Res: Off J Am Assoc Cancer Res. 2017;23(18):5374\u201383. https:\/\/doi.org\/10.1158\/1078-0432.ccr-16-2647.","journal-title":"Clin Cancer Res: Off J Am Assoc Cancer Res"},{"issue":"4","key":"3566_CR10","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1200\/jco.1990.8.4.736","volume":"8","author":"TJ Moss","year":"1990","unstructured":"Moss TJ, Sanders DG. Detection of neuroblastoma cells in blood. J Clin Oncol: Off J Am Soc Clin Oncol. 1990;8(4):736\u201340. https:\/\/doi.org\/10.1200\/jco.1990.8.4.736.","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"issue":"3","key":"3566_CR11","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/leu.2009.268","volume":"24","author":"M Br\u00fcggemann","year":"2010","unstructured":"Br\u00fcggemann M, Schrauder A, Raff T, Pfeifer H, Dworzak M, Ottmann OG, et al. Standardized MRD quantification in European ALL trials: proceedings of the second international symposium on MRD assessment in Kiel, Germany, 18\u201320 September 2008. Leukemia. 2010;24(3):521\u201335. https:\/\/doi.org\/10.1038\/leu.2009.268.","journal-title":"Leukemia"},{"issue":"12","key":"3566_CR12","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1038\/sj.leu.2403202","volume":"17","author":"JJ van Dongen","year":"2003","unstructured":"van Dongen JJ, Langerak AW, Br\u00fcggemann M, Evans PA, Hummel M, Lavender FL, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 concerted action BMH4-CT98-3936. Leukemia. 2003;17(12):2257\u2013317. https:\/\/doi.org\/10.1038\/sj.leu.2403202.","journal-title":"Leukemia"},{"issue":"3","key":"3566_CR13","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.beha.2017.07.002","volume":"30","author":"X Chen","year":"2017","unstructured":"Chen X, Wood BL. How do we measure MRD in all and how should measurements affect decisions. Re: treatment and prognosis? Best Pract Res Clin Haematol. 2017;30(3):237\u201348. https:\/\/doi.org\/10.1016\/j.beha.2017.07.002.","journal-title":"Best Pract Res Clin Haematol."},{"issue":"3","key":"3566_CR14","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/leu.2012.231","volume":"27","author":"B Denys","year":"2013","unstructured":"Denys B, van der Sluijs-Gelling AJ, Homburg C, van der Schoot CE, de Haas V, Philipp\u00e9 J, et al. Improved flow cytometric detection of minimal residual disease in childhood acute lymphoblastic leukemia. Leukemia. 2013;27(3):635\u201341. https:\/\/doi.org\/10.1038\/leu.2012.231.","journal-title":"Leukemia"},{"issue":"3","key":"3566_CR15","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1038\/sj.leu.2402387","volume":"16","author":"N Boeckx","year":"2002","unstructured":"Boeckx N, Willemse MJ, Szczepanski T, van der Velden VH, Langerak AW, Vandekerckhove P, et al. Fusion gene transcripts and Ig\/TCR gene rearrangements are complementary but infrequent targets for PCR-based detection of minimal residual disease in acute myeloid leukemia. Leukemia. 2002;16(3):368\u201375. https:\/\/doi.org\/10.1038\/sj.leu.2402387.","journal-title":"Leukemia"},{"key":"3566_CR16","doi-asserted-by":"publisher","first-page":"726","DOI":"10.3389\/fonc.2019.00726","volume":"9","author":"I Della Starza","year":"2019","unstructured":"Della Starza I, Chiaretti S, De Propris MS, Elia L, Cavalli M, De Novi LA, et al. Minimal residual disease in acute lymphoblastic leukemia: technical and clinical advances. Front Oncol. 2019;9:726. https:\/\/doi.org\/10.3389\/fonc.2019.00726.","journal-title":"Front Oncol"},{"issue":"Supplement 1","key":"3566_CR17","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1182\/blood-2018-99-117954","volume":"132","author":"I Della Starza","year":"2018","unstructured":"Della Starza I, Nunes V, Lovisa F, Silvestri D, Cavalli M, Garofalo A, et al. Digital-droplet PCR, an accurate method for IG\/TR PCR-MRD stratification in childhood acute lymphoblastic leukemia. Blood. 2018;132(Supplement 1):1544. https:\/\/doi.org\/10.1182\/blood-2018-99-117954.","journal-title":"Blood."},{"issue":"8","key":"3566_CR18","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1182\/blood-2015-07-655159","volume":"126","author":"M Kotrova","year":"2015","unstructured":"Kotrova M, Muzikova K, Mejstrikova E, Novakova M, Bakardjieva-Mihaylova V, Fiser K, et al. The predictive strength of next-generation sequencing MRD detection for relapse compared with current methods in childhood all. Blood. 2015;126(8):1045\u20137. https:\/\/doi.org\/10.1182\/blood-2015-07-655159.","journal-title":"Blood"},{"issue":"26","key":"3566_CR19","doi-asserted-by":"publisher","first-page":"3996","DOI":"10.1182\/blood-2015-03-580027","volume":"125","author":"JJ van Dongen","year":"2015","unstructured":"van Dongen JJ, van der Velden VH, Br\u00fcggemann M, Orfao A. Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies. Blood. 2015;125(26):3996\u20134009. https:\/\/doi.org\/10.1182\/blood-2015-03-580027.","journal-title":"Blood"},{"issue":"4","key":"3566_CR20","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1111\/bjh.14082","volume":"174","author":"I Della Starza","year":"2016","unstructured":"Della Starza I, Nunes V, Cavalli M, De Novi LA, Ilari C, Apicella V, et al. Comparative analysis between RQ-PCR and digital-droplet-PCR of immunoglobulin\/T-cell receptor gene rearrangements to monitor minimal residual disease in acute lymphoblastic leukaemia. Br J Haematol. 2016;174(4):541\u20139. https:\/\/doi.org\/10.1111\/bjh.14082.","journal-title":"Br J Haematol"},{"issue":"9","key":"3566_CR21","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1016\/j.bbmt.2014.04.018","volume":"20","author":"AC Logan","year":"2014","unstructured":"Logan AC, Vashi N, Faham M, Carlton V, Kong K, Bu\u00f1o I, et al. Immunoglobulin and T cell receptor gene high-throughput sequencing quantifies minimal residual disease in acute lymphoblastic leukemia and predicts post-transplantation relapse and survival. Biol Blood Marrow Transpl: J Am Soc Blood Marrow Transpl. 2014;20(9):1307\u201313. https:\/\/doi.org\/10.1016\/j.bbmt.2014.04.018.","journal-title":"Biol Blood Marrow Transpl: J Am Soc Blood Marrow Transpl"},{"issue":"3","key":"3566_CR22","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.29513","volume":"69","author":"J Bartram","year":"2022","unstructured":"Bartram J, Wright G, Adams S, Archer P, Brooks T, Edwards D, et al. High-throughput sequencing of peripheral blood for minimal residual disease monitoring in childhood precursor B-cell acute lymphoblastic leukemia: a prospective feasibility study. Pediatr Blood Cancer. 2022;69(3): e29513. https:\/\/doi.org\/10.1002\/pbc.29513.","journal-title":"Pediatr Blood Cancer."},{"issue":"11","key":"3566_CR23","doi-asserted-by":"publisher","first-page":"2838","DOI":"10.1080\/10428194.2019.1607325","volume":"60","author":"I Della Starza","year":"2019","unstructured":"Della Starza I, De Novi LA, Santoro A, Salemi D, Tam W, Cavalli M, et al. Digital droplet PCR and next-generation sequencing refine minimal residual disease monitoring in acute lymphoblastic leukemia. Leuk Lymphoma. 2019;60(11):2838\u201340. https:\/\/doi.org\/10.1080\/10428194.2019.1607325.","journal-title":"Leuk Lymphoma"},{"key":"3566_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12071738","author":"S Grassi","year":"2020","unstructured":"Grassi S, Guerrini F, Ciabatti E, Puccetti R, Salehzadeh S, Metelli MR, et al. Digital droplet PCR is a specific and sensitive tool for detecting IDH2 mutations in acute myeloid leukemia patients. Cancers. 2020. https:\/\/doi.org\/10.3390\/cancers12071738.","journal-title":"Cancers."},{"issue":"5","key":"3566_CR25","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1002\/hon.2913","volume":"39","author":"M Ansuinelli","year":"2021","unstructured":"Ansuinelli M, Della Starza I, Lauretti A, Elia L, Siravo V, Messina M, et al. Applicability of droplet digital polymerase chain reaction for minimal residual disease monitoring in Philadelphia-positive acute lymphoblastic leukaemia. Hematol Oncol. 2021;39(5):680\u20136. https:\/\/doi.org\/10.1002\/hon.2913.","journal-title":"Hematol Oncol"},{"issue":"4","key":"3566_CR26","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.jmoldx.2018.03.002","volume":"20","author":"N Coccaro","year":"2018","unstructured":"Coccaro N, Anelli L, Zagaria A, Casieri P, Tota G, Orsini P, et al. Droplet digital PCR is a robust tool for monitoring minimal residual disease in adult philadelphia-positive acute lymphoblastic leukemia. J Mol Diagn. 2018;20(4):474\u201382. https:\/\/doi.org\/10.1016\/j.jmoldx.2018.03.002.","journal-title":"J Mol Diagn"},{"issue":"7","key":"3566_CR27","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.28306","volume":"67","author":"J Saliba","year":"2020","unstructured":"Saliba J, Evensen NA, Meyer JA, Newman D, Nersting J, Narang S, et al. Feasibility of monitoring peripheral blood to detect emerging clones in children with acute lymphoblastic leukemia(\u2020). Pediatr Blood Cancer. 2020;67(7): e28306. https:\/\/doi.org\/10.1002\/pbc.28306.","journal-title":"Pediatr Blood Cancer."},{"issue":"43","key":"3566_CR28","doi-asserted-by":"publisher","first-page":"17474","DOI":"10.1073\/pnas.1312830110","volume":"110","author":"K Kawamura","year":"2013","unstructured":"Kawamura K, Cheng Y, Suzuki N, Deguchi M, Sato Y, Takae S, et al. Hippo signaling disruption and Akt stimulation of ovarian follicles for infertility treatment. Proc Natl Acad Sci USA. 2013;110(43):17474\u20139. https:\/\/doi.org\/10.1073\/pnas.1312830110.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"3566_CR29","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1093\/humrep\/deu353","volume":"30","author":"N Suzuki","year":"2015","unstructured":"Suzuki N, Yoshioka N, Takae S, Sugishita Y, Tamura M, Hashimoto S, et al. Successful fertility preservation following ovarian tissue vitrification in patients with primary ovarian insufficiency. Hum Reprod (Oxford, England). 2015;30(3):608\u201315. https:\/\/doi.org\/10.1093\/humrep\/deu353.","journal-title":"Hum Reprod (Oxford, England)"},{"key":"3566_CR30","doi-asserted-by":"publisher","first-page":"5421","DOI":"10.1038\/srep05421","volume":"4","author":"Y Fukawatase","year":"2014","unstructured":"Fukawatase Y, Toyoda M, Okamura K, Nakamura K, Nakabayashi K, Takada S, et al. Ataxia telangiectasia derived iPS cells show preserved x-ray sensitivity and decreased chromosomal instability. Sci Rep. 2014;4:5421. https:\/\/doi.org\/10.1038\/srep05421.","journal-title":"Sci Rep"},{"issue":"7","key":"3566_CR31","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1038\/nprot.2009.86","volume":"4","author":"P Kumar","year":"2009","unstructured":"Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc. 2009;4(7):1073\u201381. https:\/\/doi.org\/10.1038\/nprot.2009.86.","journal-title":"Nat Protoc"},{"key":"3566_CR32","doi-asserted-by":"publisher","DOI":"10.1002\/0471142905.hg0720s76","author":"I Adzhubei","year":"2013","unstructured":"Adzhubei I, Jordan DM, Sunyaev SR. Predicting functional effect of human missense mutations using PolyPhen-2. Curr Protoc Hum Genet. 2013. https:\/\/doi.org\/10.1002\/0471142905.hg0720s76.","journal-title":"Curr Protoc Hum Genet."},{"issue":"3","key":"3566_CR33","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1038\/ng.2892","volume":"46","author":"M Kircher","year":"2014","unstructured":"Kircher M, Witten DM, Jain P, O\u2019Roak BJ, Cooper GM, Shendure J. A general framework for estimating the relative pathogenicity of human genetic variants. Nat Genet. 2014;46(3):310\u20135. https:\/\/doi.org\/10.1038\/ng.2892.","journal-title":"Nat Genet"},{"issue":"21","key":"3566_CR34","doi-asserted-by":"publisher","first-page":"2736","DOI":"10.1200\/jco.2012.48.5680","volume":"31","author":"C Eckert","year":"2013","unstructured":"Eckert C, Henze G, Seeger K, Hagedorn N, Mann G, Panzer-Gr\u00fcmayer R, et al. Use of allogeneic hematopoietic stem-cell transplantation based on minimal residual disease response improves outcomes for children with relapsed acute lymphoblastic leukemia in the intermediate-risk group. J Clin Oncol: Off J Am Soc Clin Oncol. 2013;31(21):2736\u201342. https:\/\/doi.org\/10.1200\/jco.2012.48.5680.","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"issue":"1","key":"3566_CR35","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1053\/beha.2002.0184","volume":"15","author":"T Szczepa\u0144ski","year":"2002","unstructured":"Szczepa\u0144ski T, Flohr T, van der Velden VH, Bartram CR, van Dongen JJ. Molecular monitoring of residual disease using antigen receptor genes in childhood acute lymphoblastic leukaemia. Best Pract Res Clin Haematol. 2002;15(1):37\u201357. https:\/\/doi.org\/10.1053\/beha.2002.0184.","journal-title":"Best Pract Res Clin Haematol"},{"issue":"4","key":"3566_CR36","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1038\/leu.2008.5","volume":"22","author":"T Flohr","year":"2008","unstructured":"Flohr T, Schrauder A, Cazzaniga G, Panzer-Gr\u00fcmayer R, van der Velden V, Fischer S, et al. Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia. Leukemia. 2008;22(4):771\u201382. https:\/\/doi.org\/10.1038\/leu.2008.5.","journal-title":"Leukemia"},{"issue":"4","key":"3566_CR37","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1038\/sj.leu.2404586","volume":"21","author":"VH van der Velden","year":"2007","unstructured":"van der Velden VH, Cazzaniga G, Schrauder A, Hancock J, Bader P, Panzer-Grumayer ER, et al. Analysis of minimal residual disease by Ig\/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data. Leukemia. 2007;21(4):604\u201311. https:\/\/doi.org\/10.1038\/sj.leu.2404586.","journal-title":"Leukemia"},{"issue":"2","key":"3566_CR38","doi-asserted-by":"publisher","first-page":"e347","DOI":"10.1097\/hs9.0000000000000347","volume":"4","author":"D Drandi","year":"2020","unstructured":"Drandi D, Alcantara M, Benmaad I, S\u00f6hlbrandt A, Lhermitte L, Zaccaria G, et al. Droplet digital PCR quantification of mantle cell lymphoma follow-up samples from four prospective trials of the European MCL network. HemaSphere. 2020;4(2):e347. https:\/\/doi.org\/10.1097\/hs9.0000000000000347.","journal-title":"HemaSphere."},{"issue":"6","key":"3566_CR39","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1038\/leu.2013.375","volume":"28","author":"M Ladetto","year":"2014","unstructured":"Ladetto M, Br\u00fcggemann M, Monitillo L, Ferrero S, Pepin F, Drandi D, et al. Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders. Leukemia. 2014;28(6):1299\u2013307. https:\/\/doi.org\/10.1038\/leu.2013.375.","journal-title":"Leukemia"},{"issue":"18","key":"3566_CR40","doi-asserted-by":"publisher","first-page":"2917","DOI":"10.1200\/jco.2006.06.5888","volume":"24","author":"SJ Lee","year":"2006","unstructured":"Lee SJ, Schover LR, Partridge AH, Patrizio P, Wallace WH, Hagerty K, et al. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol: Off J Am Soc Clin Oncol. 2006;24(18):2917\u201331. https:\/\/doi.org\/10.1200\/jco.2006.06.5888.","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"issue":"10","key":"3566_CR41","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1038\/bmt.2017.147","volume":"52","author":"A Balduzzi","year":"2017","unstructured":"Balduzzi A, Dalle JH, Jahnukainen K, von Wolff M, Lucchini G, Ifversen M, et al. Fertility preservation issues in pediatric hematopoietic stem cell transplantation: practical approaches from the consensus of the pediatric diseases working party of the EBMT and the international BFM study group. Bone Marrow Transpl. 2017;52(10):1406\u201315. https:\/\/doi.org\/10.1038\/bmt.2017.147.","journal-title":"Bone Marrow Transpl"},{"issue":"9443","key":"3566_CR42","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1016\/s0140-6736(04)17222-x","volume":"364","author":"J Donnez","year":"2004","unstructured":"Donnez J, Dolmans MM, Demylle D, Jadoul P, Pirard C, Squifflet J, et al. Livebirth after orthotopic transplantation of cryopreserved ovarian tissue. Lancet. 2004;364(9443):1405\u201310. https:\/\/doi.org\/10.1016\/s0140-6736(04)17222-x.","journal-title":"Lancet"},{"issue":"12","key":"3566_CR43","doi-asserted-by":"publisher","first-page":"2838","DOI":"10.1093\/humrep\/dev230","volume":"30","author":"AK Jensen","year":"2015","unstructured":"Jensen AK, Kristensen SG, Macklon KT, Jeppesen JV, Fedder J, Ernst E, et al. Outcomes of transplantations of cryopreserved ovarian tissue to 41 women in Denmark. Hum Reprod (Oxford, England). 2015;30(12):2838\u201345. https:\/\/doi.org\/10.1093\/humrep\/dev230.","journal-title":"Hum Reprod (Oxford, England)"},{"issue":"2","key":"3566_CR44","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.fertnstert.2016.04.031","volume":"106","author":"D Meirow","year":"2016","unstructured":"Meirow D, Ra\u2019anani H, Shapira M, Brenghausen M, Derech Chaim S, Aviel-Ronen S, et al. Transplantations of frozen-thawed ovarian tissue demonstrate high reproductive performance and the need to revise restrictive criteria. Fertil Steril. 2016;106(2):467\u201374. https:\/\/doi.org\/10.1016\/j.fertnstert.2016.04.031.","journal-title":"Fertil Steril"},{"issue":"17","key":"3566_CR45","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1056\/NEJMra1614676","volume":"377","author":"J Donnez","year":"2017","unstructured":"Donnez J, Dolmans MM. Fertility preservation in women. N Engl J Med. 2017;377(17):1657\u201365. https:\/\/doi.org\/10.1056\/NEJMra1614676.","journal-title":"N Engl J Med"},{"issue":"1","key":"3566_CR46","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.fertnstert.2017.09.001","volume":"109","author":"M Shapira","year":"2018","unstructured":"Shapira M, Raanani H, Barshack I, Amariglio N, Derech-Haim S, Marciano MN, et al. First delivery in a leukemia survivor after transplantation of cryopreserved ovarian tissue, evaluated for leukemia cells contamination. Fertil Steril. 2018;109(1):48\u201353. https:\/\/doi.org\/10.1016\/j.fertnstert.2017.09.001.","journal-title":"Fertil Steril"},{"issue":"12","key":"3566_CR47","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1007\/s10815-018-1315-1","volume":"35","author":"SJ Silber","year":"2018","unstructured":"Silber SJ, DeRosa M, Goldsmith S, Fan Y, Castleman L, Melnick J. Cryopreservation and transplantation of ovarian tissue: results from one center in the USA. J Assist Reprod Genet. 2018;35(12):2205\u201313. https:\/\/doi.org\/10.1007\/s10815-018-1315-1.","journal-title":"J Assist Reprod Genet"},{"key":"3566_CR48","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9103196","author":"C Hossay","year":"2020","unstructured":"Hossay C, Donnez J, Dolmans MM. Whole ovary cryopreservation and transplantation: a systematic review of challenges and research developments in animal experiments and humans. J Clin Med. 2020. https:\/\/doi.org\/10.3390\/jcm9103196.","journal-title":"J Clin Med."},{"issue":"5","key":"3566_CR49","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1093\/humupd\/dmt020","volume":"19","author":"L Bastings","year":"2013","unstructured":"Bastings L, Beerendonk CC, Westphal JR, Massuger LF, Kaal SE, van Leeuwen FE, et al. Autotransplantation of cryopreserved ovarian tissue in cancer survivors and the risk of reintroducing malignancy: a systematic review. Hum Reprod Update. 2013;19(5):483\u2013506. https:\/\/doi.org\/10.1093\/humupd\/dmt020.","journal-title":"Hum Reprod Update"},{"issue":"16","key":"3566_CR50","doi-asserted-by":"publisher","first-page":"2908","DOI":"10.1182\/blood-2010-01-265751","volume":"116","author":"MM Dolmans","year":"2010","unstructured":"Dolmans MM, Marinescu C, Saussoy P, Van Langendonckt A, Amorim C, Donnez J. Reimplantation of cryopreserved ovarian tissue from patients with acute lymphoblastic leukemia is potentially unsafe. Blood. 2010;116(16):2908\u201314. https:\/\/doi.org\/10.1182\/blood-2010-01-265751.","journal-title":"Blood"},{"issue":"5","key":"3566_CR51","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1093\/humrep\/den055","volume":"23","author":"D Meirow","year":"2008","unstructured":"Meirow D, Hardan I, Dor J, Fridman E, Elizur S, Ra\u2019anani H, et al. Searching for evidence of disease and malignant cell contamination in ovarian tissue stored from hematologic cancer patients. Hum Reprod (Oxford, England). 2008;23(5):1007\u201313. https:\/\/doi.org\/10.1093\/humrep\/den055.","journal-title":"Hum Reprod (Oxford, England)"},{"issue":"1","key":"3566_CR52","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s10815-012-9912-x","volume":"30","author":"M Rosendahl","year":"2013","unstructured":"Rosendahl M, Greve T, Andersen CY. The safety of transplanting cryopreserved ovarian tissue in cancer patients: a review of the literature. J Assist Reprod Genet. 2013;30(1):11\u201324. https:\/\/doi.org\/10.1007\/s10815-012-9912-x.","journal-title":"J Assist Reprod Genet"},{"issue":"3","key":"3566_CR53","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.fertnstert.2015.05.021","volume":"104","author":"M Soares","year":"2015","unstructured":"Soares M, Sahrari K, Amorim CA, Saussoy P, Donnez J, Dolmans MM. Evaluation of a human ovarian follicle isolation technique to obtain disease-free follicle suspensions before safely grafting to cancer patients. Fertil Steril. 2015;104(3):672-80.e2. https:\/\/doi.org\/10.1016\/j.fertnstert.2015.05.021.","journal-title":"Fertil Steril"},{"issue":"10","key":"3566_CR54","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1093\/humrep\/dew193","volume":"31","author":"MM Dolmans","year":"2016","unstructured":"Dolmans MM, Iwahara Y, Donnez J, Soares M, Vaerman JL, Amorim CA, et al. Evaluation of minimal disseminated disease in cryopreserved ovarian tissue from bone and soft tissue sarcoma patients. Hum Reprod (Oxford, England). 2016;31(10):2292\u2013302. https:\/\/doi.org\/10.1093\/humrep\/dew193.","journal-title":"Hum Reprod (Oxford, England)"},{"issue":"2","key":"3566_CR55","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1111\/bjh.14657","volume":"178","author":"M Soares","year":"2017","unstructured":"Soares M, Saussoy P, Maskens M, Reul H, Amorim CA, Donnez J, et al. Eliminating malignant cells from cryopreserved ovarian tissue is possible in leukaemia patients. Br J Haematol. 2017;178(2):231\u20139. https:\/\/doi.org\/10.1111\/bjh.14657.","journal-title":"Br J Haematol"},{"issue":"5","key":"3566_CR56","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1093\/humrep\/deaa353","volume":"36","author":"TYT Nguyen","year":"2021","unstructured":"Nguyen TYT, Cacciottola L, Camboni A, Ravau J, De Vos M, Demeestere I, et al. Ovarian tissue cryopreservation and transplantation in patients with central nervous system tumours. Hum Reprod (Oxford, England). 2021;36(5):1296\u2013309. https:\/\/doi.org\/10.1093\/humrep\/deaa353.","journal-title":"Hum Reprod (Oxford, England)"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-023-03566-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-023-03566-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-023-03566-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,28]],"date-time":"2023-05-28T08:03:42Z","timestamp":1685261022000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-023-03566-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,3]]},"references-count":56,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["3566"],"URL":"https:\/\/doi.org\/10.1007\/s12185-023-03566-2","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,3]]},"assertion":[{"value":"12 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Authors declare no conflicts of interest for this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}